Objective:To study the effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma. Methods: 138 patients diagnosed with bro...Objective:To study the effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma. Methods: 138 patients diagnosed with bronchial asthma in our hospital between August 2014 and February 2016 were selected and randomly divided into two groups (n=69), observation group received oral montelukast combined with symbicort inhalation treatment, and control group received symbicort inhalation treatment. 3 months and 6 months after treatment, spirometer was used to measure the airway function parameters, and enzyme-linked immunosorbent assay kits were used to determine Th1/Th2, Treg/Th17 and Th9/cTfh cytokine content. Results:3 months and 6 months after treatment, 1 second (FEV1)/forced vital capacity (FVC), tidal expiratory flow at 25%, 50%and 75%of tidal volume (TEF25%, TEF50%and TEF75%) of observation group were significantly higher than those of control group (P<0.05);serum interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-10 and transforming growth factor (TGF-β) levels of observation group were significantly higher than those of control group (P<0.05) while IL-4, IL-6, IL-17, IL-22, IL-9 and IL-21 levels were significantly lower than those of control group (P<0.05). Conclusions:Montelukast combined with conventional inhalation treatment of bronchial asthma can more effectively improve the airway function and inhibit the airway inflammatory response mediated by Th1/Th2, Treg/Th17 and Th9/cTfh imbalance.展开更多
文摘Objective:To study the effect of glucocorticoid inhalation combined with oral montelukast on airway function and serum inflammatory cytokines in patients with bronchial asthma. Methods: 138 patients diagnosed with bronchial asthma in our hospital between August 2014 and February 2016 were selected and randomly divided into two groups (n=69), observation group received oral montelukast combined with symbicort inhalation treatment, and control group received symbicort inhalation treatment. 3 months and 6 months after treatment, spirometer was used to measure the airway function parameters, and enzyme-linked immunosorbent assay kits were used to determine Th1/Th2, Treg/Th17 and Th9/cTfh cytokine content. Results:3 months and 6 months after treatment, 1 second (FEV1)/forced vital capacity (FVC), tidal expiratory flow at 25%, 50%and 75%of tidal volume (TEF25%, TEF50%and TEF75%) of observation group were significantly higher than those of control group (P<0.05);serum interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor (TNF-α), IL-10 and transforming growth factor (TGF-β) levels of observation group were significantly higher than those of control group (P<0.05) while IL-4, IL-6, IL-17, IL-22, IL-9 and IL-21 levels were significantly lower than those of control group (P<0.05). Conclusions:Montelukast combined with conventional inhalation treatment of bronchial asthma can more effectively improve the airway function and inhibit the airway inflammatory response mediated by Th1/Th2, Treg/Th17 and Th9/cTfh imbalance.
